MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/2162402x.2024.2372886

Медицинская библиотека · Oncoimmunology · 2024

Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade.

Ree Anne Hansen, Høye Eirik, Esbensen Ying, Beitnes Ann-Christin R, Negård Anne, Bernklev Linn, Tetlie Linn Kruse, Fretland Åsmund A, Hamre Hanne M, Kersten Christian, Hofsli Eva, Guren Marianne G, Sorbye Halfdan, Nilsen Hilde L, Flatmark Kjersti, Meltzer Sebastian

Клинический случайСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

The randomized METIMMOX trial (NCT03388190) examined if patients with previously untreated, unresectable abdominal metastases from microsatellite-stable (MSS) colorectal cancer (CRC) might benefit from potentially immunogenic, short-course oxaliplatin-based chemotherapy alternating with immune checkpoint blockade (ICB). Three of 38 patients assigned to this experimental treatment had metastases from BRAF-mutant MSS-CRC, in general a poor-prognostic subgroup explored here. The ≥70-year-old females presented with ascending colon adenocarcinomas with intermediate tumor mutational burden (6.2-11.8 mutations per megabase). All experienced early disappearance of the primary tumor followed by complete response of all overt metastatic disease, resulting in progression-free survival as long as 20-35 months. However, they encountered recurrence at previously unaffected sites and ultimately sanctuary organs, or as intrahepatic tumor evolution reflected in the terminal loss of initially induced T-cell clonality in liver metastases. Yet, the remarkable first-line responses to short-course oxaliplatin-based chemotherapy alternating with ICB may offer a novel therapeutic option to a particularly hard-to-treat MSS-CRC subgroup.

Для цитирования: Ree Anne Hansen, Høye Eirik, Esbensen Ying, Beitnes Ann-Christin R, Negård Anne, Bernklev Linn, Tetlie Linn Kruse, Fretland Åsmund A, Hamre Hanne M, Kersten Christian, Hofsli Eva, Guren Marianne G, Sorbye Halfdan, Nilsen Hilde L, Flatmark Kjersti, Meltzer Sebastian. Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade.. Oncoimmunology. 2024. DOI: 10.1080/2162402x.2024.2372886.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.